Interaction Between Inflammatory State and Neurochemical Changes in Major Psychiatric Disorders by Aye Mu Myint & Markus J Schwarz
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
8 
Interaction Between Inflammatory State  
and Neurochemical Changes in  
Major Psychiatric Disorders 
Aye Mu Myint and Markus J Schwarz 
Psychiatric Hospital 
Ludwig-Maximilian University 
Munich,  
Germany 
1. Introduction 
Inflammation is the immunological mechanism to react against danger signal. In old days, 
inflammation is characterized by heat, redness, pain, swelling and loss of function in gross 
appearance and inflammatory cells infiltration to the affected area in microscopical 
appearance. Even though it is not always possible to demonstrate the inflammatory cells 
infiltration in certain part of brain area in patients with psychiatric disorders, there are 
evidences such as enhanced production of inflammatory mediators that indicated the 
reaction of the immune system. It is generally considered that immune reactions occur in 
response to a danger signal such as abnormal cell death. With time, scientists in both 
immunology and neuroscience fields realized that the danger signals occur not only due to 
microorganisms, foreign bodies or tissue injury but also some noxious situations such as 
psychological or emotional stress. 
The involvement of immune system in psychiatric disorders is, in fact, recognized since 1927 
by Wagner-Jauregg, the only psychiatrist who ever awarded Noble prize for his work on 
malaria inoculation in treatment of dementia paralytica (Raju, 1998) which was the 
treatment of psychosis by inducing fever, known as ‘pyrotherapy’. That evidence indicated 
that the immune activation induced by infection could cure the psychotic symptoms since 
fever is associated to immune activation. On the other hand meningitis induced toxic 
psychosis without fever was reported by Fischer, 1963. Taken together, in the field of 
Medicine, the relation between infection, inflammation, fever and psychotic symptoms 
became of interest since early 20th Century. Around similar period, in the field of Biology, 
Selye (Selye, 1954) has reported that the neurogenic stress situation induced by forcible 
immobilization could effectively inhibit inflammation in the experimental granuloma-pouch 
under the dorsal skin of rat after chronic irritation with cotton wool and that reaction was 
abolished in adrenalectomized rats. That finding indicated that the anti-phlogistic effect or 
suppression of immune activation was largely dependent on secretion of anti-phlogistic 
corticoids from the adrenal glands. That was the earliest starting point indicating the effect 
of stress on the immune system although it was difficult to conclude if the immobilization is 
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physical or emotional stress, in other words, if that suppression of immune activation 
induced by external agent came centrally.  
In 1975, Ader and Cohen reported that immune suppression could be induced by 
behavioural condition (Ader and Cohen, 1975). That was the clear demonstration that 
peripheral immune system could be influenced by emotion or behavioural manipulation. In 
the following years, the body and brain crosstalk through immune system became of 
interest in pathophysiology of psychiatric disorders. In 1987, the low natural killer cell 
activity in patients with depression was reported (Irwin et al., 1987). In early 1990s “sickness 
behaviour” was proposed as peripheral immune activation induced depressive like 
behaviour based on the fact that injection of bacterial toxin, lipopolysaccharide, peripherally 
could induce depressive like behaviour (Bluthe et al., 1992). They also reported that sickness 
behaviour induced by peripheral immune activation was reversed by administering the 
antagonist of interleukin-1 (IL1) receptor. While sickness behaviour is, unlike major 
depressive disorders, a short term syndrome, the symptoms of sickness behaviour such as 
lack of interest, inability to concentrate, loss of appetite, disturbance of sleep and social 
anhedonia are the similar symptoms as in depression. Thus, immune activation in the 
periphery was considered as part of the pathophysiological mechanisms of major 
depression and anti inflammatory medication or manipulation of immune system became of 
new therapeutic interest. 
The first theory on the immune activation in psychiatric disorders proposed was 
“macrophage theory of depression” (Smith, 1991) in which the association between cytokine 
secreted from macrophage and hypothalamus activity were proposed as pathophysiological 
mechanism of major depressive disorder.  This theory has highlighted the interaction 
between immune system and endocrine system which could influence the emotion and 
higher function of the human brain. Based on the finding related to the connection between 
lymphocyte function, hypothalamo-hypophysial-adrenal axis and depression which 
indicated the impaired lymphocyte response to mitogen stimulation (Maes et al., 1989), the 
macrophage theory of depression was extended to monocyte-lymphocyte hypothesis of 
depression (Maes et al., 1995). The same authors have also extended the hypothesis to 
another major psychiatric disorder, schizophrenia (Smith and Maes, 1995). It was discussed 
that the cytokines, such as, IL1 and IL2 in low concentration could enhance the 
dopaminergic neurotransmission whereas high IL2 could suppress it. Around this period, 
the impairment of neutrophil and macrophage phagocytoses in depressed patients was also 
reported (McAdams and Leonard, 1993). Changes in immunoglobulin, complement and 
acute phase protein levels were also reported in patients with depression (Song et al., 1994). 
Also in late 1080s, Nishino and colleagues has first demonstrated the prostaglandin E2 
(PGE2), an enzyme involved in inflammatory process is increased in the saliva of depressed 
patients (Nishino et al., 1989).  
Based on the different subtypes of immune cells, some studies explore the ratios between 
different subsets of T-lymphocytes and demonstrated the higher T-helper/T-suppressor 
cytotoxic cell ratio in depressed patients (Maes et al., 1992). The enhanced T-helper type 1 
immune response which is associated with development of inflammation was proposed in 
major depressive disorders. Similar development in research related to inflammatory 
response and schizophrenia also occur around this later 20th Century and the beginning of 
21st Century. The increased T-helper type 2 cells in the blood of patients with schizophrenia 
were reported and the dominance of T-helper type 2 reaction was suggested (Sperner-
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Unterweger et al., 1999). Based on this finding “Th-2 hypothesis of schizophrenia” was 
proposed (Schwarz et al., 2001). Around the same period in the beginning of 21st Century, 
the tryptophan degradation induced by the indoleamine 2,3-dioxygenase (IDO) enzyme in 
the presence of inflammatory state became of interest as a link between immune function 
and serotonergic abnormalities due to reduced tryptophan availability (Capuron et al., 2002; 
Maes et al., 2002). A year later, the possible involvement of downstream tryptophan 
metabolites in terms of neurotoxic changes in major depressive disorders and further 
immune system and NMDA-glutermatergic neurotransmission interaction were proposed 
in “neurodegeneration hypothesis of depression” (Myint and Kim, 2003).  
Several therapeutic strategies have been studied in the area of immune activation and 
psychiatric disorders. The antagonist of pro-inflammatory cytokine such as tumour necrosis 
factor- (TNF), eternacept, and n3 fatty acids are those studied and given some promising 
results. Recently, add-on therapy with inhibitor of cyclooxygenase-2 (COX-2) enzyme, 
celecoxib which was originally an anti-inflammatory medication was reported to enhance 
the response to both anti-depressant therapy and anti-psychotic therapy. Moreover, the 
possible use of inflammatory based biomarkers in diagnosis and choice of medication in 
major psychiatric disorders are considered. 
In this chapter, brief basic immunology on inflammation, findings and mechanisms related 
to inflammatory state in psychiatric disorders, the immune-endocrine interaction, immune-
endocrine-tryptophan metabolism interaction and inflammation-tryptophan metabolism-
neurochemicals interaction network were explained and discussed. 
2. Inflammatory state 
2.1 A short survey of the body’s defence system 
The body’s defense system is a complex arrangement of physical, chemical, biochemical, 
and cellular barriers. Here we will focus on immunity, which is the result of the interplay 
between two "immune" systems: the innate immune system, which is phylogenetically 
older, and the adaptive immune system of T and B cells (Medzhitov and Janeway-CA, 1998). 
The innate immune system functions in an antigen-nonspecific way, while antigen-specific 
mechanisms are mediated by the adaptive one. Characteristic cells of the innate immune 
system are e.g. granulocytes, natural killer (NK) cells, monocytes/macrophages, or dendritic 
cells. The innate immune system is the first line of defense against infection and it provides 
signals for the activation of the adaptive immune system. Innate responses serve to regulate 
the onset, duration, magnitude, and character of the antibody- and cell-mediated adaptive 
response. In contrast to the adaptive immune system, the innate immune system is not able 
to confer long-lasting memory, i.e. immunity against a specific pathogen.  
In the late 1980s, Janeway proposed the model of the antigen-presenting cells, which are 
able to recognize and differentiate distinct groups of microbes by special receptors, the so-
called pattern-recognition receptors (Janeway, Jr., 1989). The identification of pathogen-
associated molecular patterns or microbe-associated molecular patterns by the innate 
immune system allows the body’s defense system to discriminate between “infectious non-
self” and “non-infectious self”. This concept was expanded by Matzinger’s hypothesis of 
danger signals as inducers of the body’s defense system (Matzinger, 1994). According to this 
new concept, immunological phenomena like autoimmunity, sterile inflammation, or the 
acceptance of the fetus, who is immunologically 50% non-self, by the mother’s immune 
system can be explained. Matzinger proposed that antigen presenting cells are not activated 
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by an infectious non-self signal, but by danger signals from injured host cells, damaged 
tissues, or metabolic stress. According to the term “pathogen-associated molecular 
patterns”, she introduced the term “damage-associated molecular patterns” for these 
endogenous danger signals.  
 
 
Fig. 1. Both arms of the cellular immune system (adapted from Drexhage et al., 2010). 
The innate immune system provides a broad array of different receptors for the 
identification of both kinds of molecular patterns. The best known group of receptors is the 
family of Toll-like receptors (TLRs), which are able to recognize both, exogenous and 
endogenous molecular patterns (Medzhitov, 2009). TLR4 for example recognizes the 
pathogen-associated molecular pattern of bacterial lipopolysaccharide as well as the 
damage-associated molecular patterns of endogenous heat-shock proteins, while TLR3 is an 
intracellular recognition receptor of both, viral and self double-stranded DNA (Sirisinha, 
2011). To limit an overshooting immune response to the minimum necessary tissue damage, 
the innate immune system is down-regulated by several negative regulators such as soluble 
decoy TLRs and intracellular TLR regulators like suppressors of cytokine signals (SOCS) 
and the enzyme A20 (Sirisinha, 2011). 
The cells of the adaptive immune system are T cells (bearing the / T cell receptor) and B 
cells. The adaptive immune system induces T cells to change from a naive phenotype to 
either an effector functional type or a memory phenotype. The T cells are principally 
subdivided into CD4 and CD8 T cells, according to their surface receptors with affinity to 
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either the major histocompatibility complex II (CD4) or I (CD8). CD4, or helper T cells, are 
specialized to activate other cells and fall into distinct functional classes. More than twenty 
years ago, the dichotomy of Th1 and Th2 cells was introduced. The main function of Th1 
cells (sometimes known as inflammatory T cells) is to fight against intracellular pathogens 
and to activate macrophages to kill the pathogens they harbor, while Th2 cells activate B 
cells to produce antibodies against extracellular pathogens (Janeway et al., 2001). More 
recently, other T helper cell subsets have been identified with Th17 cells being the most 
prominent ones. Th17 cells are specialized in clearing pathogens that cannot be handled by 
Th1 or Th2 cells including some bacteria and fungi (Jager and Kuchroo, 2010). In addition to 
these effector cells, CD4 T cells can also have regulatory properties; the most prominent are 
the regulatory T cells (Treg) cells, who are responsible for the downregulation of the T 
helper cell-mediated immune response. Their major function is therefore to maintain self-
tolerance and immune homeostasis.  
The function of CD8 T cells is to identify infected cells via the interaction of their surface 
protein CD8 with the antigen bearing MHC I receptor and to kill these cells by destructing 
their membrane. In analogy to the T helper subsets, CD8 cells can also form subsets like Tc2 
and Tc17. The phylogenetically old form of T cells, characterized by the gamma/delta T cell 
receptor (‘/T-cells’) is not easily subsumed to either the adaptive or the innate immune 
system, since it combines some characteristics of CD4 T cells, CD8 T  cells, and NK cells. 
Cytokines and chemokines, the transmitters/hormones of the immune system, help to 
determine the particular type of adaptive response and the expression of costimulatory cell 
surface molecules that are required for efficient immune cell activation. T helper cell subsets 
are characterised by their respective cytokine profile. Typical Th1-like cytokines are 
Interferon- (IFN-), Interleukin-2 (IL-2), and IL-12, typical Th2 cytokines are IL-4, IL-10 (in 
the mouse, not in humans), IL-13 and others (Del Prete, 1992). IL-23 induces the subset of 
Th17 cells, which are characterized by the production of the partly redundant cytokines IL-
17A and IL-17F; both cytokines promote tissue inflammation via induction of the production 
of pro-inflammatory cytokines like IL-1, IL-6, TNF and pro-inflammatory chemokines like 
CXCL1 and IL-8 (Jager and Kuchroo, 2010). However, the cytokines and chemokines are 
orchestrated in an extremely complex way and most of the effects are dependent on the 
simultaneous production of different cytokines. The generation of the aggressive Th17 cells, 
for example, requires the presence of the anti-inflammatory cytokine TGF-b together with 
the multifunctional cytokine IL-6, while TGF-b alone induces the development of 
immunosuppressive Treg cells (Jager and Kuchroo, 2010).  
Besides the cellular components of the two immune systems, the humoral (i.e. soluble) 
components are the complement system and the acute phase proteins within the innate 
system and the antibodies, produced by activated B cells within the adaptive system. 
2.2 The immune-brain connection 
There is a strong relationship between the cytokine system and the neurotransmitter system. 
In vitro- and in vivo studies showed the modulating effect of interferons on the production 
of prolactin (Vankelecom et al., 1997) and – particularly interesting with regard to 
psychopathology – on the catecholaminergic, dopaminergic, serotonergic und glutamatergic 
neurotransmitter systems, e.g. the induction of transcriptional activity of the serotonin 
transporter (Kamata et al., 2000; Morikawa et al., 1998; Shuto et al., 1997; Katafuchi et al., 
1995). TNF- regulates the secretion of norepinephrine in the brain (Nickola et al., 2001). 
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Peripheral administration of TNF- induces the cerebral tryptophan content (Ando and 
Dunn, 1999) and the synthesis of serotonin and dopamine (Hayley et al., 2002). There is 
experimental evidence that IL-1 can activate the serotonin transporter thereby increasing the 
reuptake of serotonin from the synaptic cleft (Ramamoorthy et al., 1995). Furthermore, IL-1 
activates the serotonergic system (Gemma et al., 1997). The considerable overlap in 
biological activities of IL-1 and 5-HT indicates that the interactions between these two 
systems may be involved in the modulation of behaviour.  
IL-2 can affect gene expression, neuronal activity and neurotransmitter release in brain 
regions, subserving sleep, memory and cognition, locomotion, and neuroendocrine function. 
IL-2 modulates neurotranmission of acetylcholine, dopamine, and norepinephrine in a 
biphasic manner (Petitto et al., 1997). It appears to be a potent and specific regulator of 
neurotransmission in frontal cortex, hippocampus, striatum, and hypothalamus (Hanisch 
and Quirion, 1995). 
IL-6 is produced by neurons, astrocytes and microglia (Van Wagoner and Benveniste, 1999). 
This cytokine promotes neuronal differentiation and survival (Gadient and Otten, 1997) and 
modulates the above summarized neurotransmitter systems (Song et al., 1999; Qiu et al., 
1995; Qiu et al., 1998). Several studies have investigated the influence of IL-6 on the 
production, release, and metabolism of 5-HT. Peripherally administered IL-6 increases the 
concentrations of tryptophan and the serotonin metabolite 5-hydroxyindole acetic acid (5-
HIAA) in the brain (Wang and Dunn, 1999; Wang and Dunn, 1998; Zalcman et al., 1994) and 
it has been proposed that the interaction between IL-6 and brain serotonin is a complex 
process (Barkhudaryan and Dunn, 1999).  
2.3 Stress and CNS immune system  
The effect of chronic stress on the peripheral immune system and its relevance for MD has 
extensively been discussed (O'brien et al., 2004). Recent in vivo evidence now suggests that 
stress-induced elevation of glucocorticoids also enhances immune function within the CNS 
through microglia activation and proliferation and with a loss in the number and volume of 
astrocytes (Czeh et al., 2005). Animal studies show that stress induces an enhanced 
expression of proinflammatory factors such as IL-1 (Pugh et al., 1999; Nguyen et al., 1998), 
macrophage migration inhibitory factor (MIF) (Bacher et al., 1998; Niino et al., 2000; Suzuki 
et al., 2000) and cyclooxygenase-2 (COX-2) (Madrigal et al., 2003) in the brain. Elevation of 
these proinflammatory factors is accompanied by dendritic atrophy and neuronal death 
within the hippocampus (Sapolsky, 1985; Woolley et al., 1990), which are also found in 
brains of subjects with MD. These detrimental effects of glucocorticoids in the CNS are 
mediated by a rise in extracellular glutamate (Moghaddam et al., 1994; Stein-Behrens et al., 
1994) and subsequent over-stimulation of the NMDA receptor. Such an over-stimulation of 
the NMDA receptor results in excitotoxic neuronal damage (Takahashi et al., 2002). Nair and 
Bonneau could demonstrate that restraint-induced psychological stress stimulates 
proliferation of microglia, which was prevented by blockade either of corticosterone 
synthesis, of the glucocorticoid receptor, or of the NMDA receptor (Nair and Bonneau, 
2006). These data show that stress-induced microglia proliferation is mediated by 
corticosterone-induced and NMDA receptor-mediated activation within the CNS. 
Moreover, NMDA receptor activation during stress leads again to increased expression of 
the enzyme COX-2 and its product prostaglandin E2 (PGE2), which in turn is able to 
stimulate microglia activation. Therefore, a vicious circle may be induced, if the stress 
response is not limited, as it is discussed in MD. 
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2.4 Inflammatory state in major psychiatric disorders 
2.4.1 Schizophrenia 
Several epidemiologic studies give strong evidence for urbanicity at birth and upbringing to 
be a major risk factor for schizophrenia (Pedersen and Mortensen, 2001; Mortensen et al., 
1999; Lewis et al., 1992). Another well replicated aspect is the seasonality of birth with a 5-
8% excess of winter and spring births for individuals who later develop schizophrenia 
(Torrey et al., 1997). Both, urbanicity and saisonality, support the idea of a pre- or perinatal 
exposure to a viral infection as being a risk factor for developing schizophrenia (Franzek 
and Beckmann, 1996; Yolken and Torrey, 1995). In recent years, accumulating data showed 
the significant association between maternal infection during pregnancy with a higher risk 
for the offspring to develop schizophrenia (Brown and Patterson, 2011). Thus, a 
neurodevelopmental insult resulting from a prenatal viral infection, or a latent postnatal 
(viral?) infection may be associated with a chronic immune activation, possibly leading to a 
kind of mild autoimmune reaction, or a chronic, latent ‘mild encephalitis’ (Bechter, 2001). 
Recent animal experiments strongly support this concept (Vuillermot et al., 2010). 
There are several lines of evidence for a mild activation of the immune system in 
schizophrenia. Some investigators dealt with antibody titres, some with cellular markers 
and others with cytokine measurements in serum, CSF, or in vitro from stimulated 
peripheral immune cells. Different hypotheses have been published according to the 
findings, e.g. the hypothesis of dopamine receptor activating autoantibodies (Knight, 1982), 
activated monocytes (Smith, 1992), a predominance of the Th2 system (Schwarz et al., 2001), 
or a deficiency of autoimmune T cells (Kipnis et al., 2006) playing a key role in the 
pathophysiology of schizophrenia.  
A considerable number of reports show elevated antibody titers against several antigens in 
schizophrenic patients. The first report on antibodies against brain tissue in cerebrospinal 
fluid (CSF) of schizophrenic patients was published in the 1930ies by Lehmann-Facius 
(Lehmann-Facius, 1937). Others followed, describing anti-neuronal and non-CNS-specific 
auto-antibodies, or anti-viral antibodies in schizophrenia (e.g. (Heath et al., 1989; Schwarz et 
al., 1999; Torrey et al., 1982), for review see (Gaughran, 2002)). Some data suggest a role for 
endogenous retroviruses that may be activated by endocrine changes during adolescence 
and early adulthood – the main age at onset – or during an exogenous virus infection 
(Karlsson et al., 2001; Leweke et al., 2002).  
However, no disease-specific pathogen could be identified up to now. The situation is 
comparable with the field of Multiple Sclerosis research, where strong evidence points to an 
infectious/autoimmune pathogenesis, but where the causative pathogen is still unknown. 
Regarding the cytokine profile, Potvin and coworkers (Potvin et al., 2007) reported in their 
systematic review of changes in seven cytokines in patients with schizophrenia that the IL-1 
receptor antagonist (IL-1RA), soluble IL-2r and IL-6 were increased in the serum of 
schizophrenia patients while in vitro IL-2 synthesis was decreased. IL-1 is a potent pro-
inflammatory mediator, inducing febrile response, production of acute phase proteins and 
activating e.g. T cells, B cells; its soluble receptor antagonist blocks these effects und is 
therefore acting as an anti-inflammatory agent (Gabay et al., 2010). The soluble IL-2 receptor 
is shed from the surface of activated immune cells and blocks the pro-inflammatory action 
of IL-2 (Nelson and Willerford, 1998). In contrast, IL-6 is a pluripotent cytokine, which exerts 
not only pro-inflammatory activity, but also regulates the balance between Th17 and Treg 
cells (Neurath and Finotto, 2011). Since it has a broad array of functions, it is difficult to 
interpret its role in the presence of elevated IL-1RA and sIL-2R levels. It is important to keep 
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in mind that immune measures, especially measurement of cytokines, in schizophrenic 
patients are limited by confounding factors. Factors influencing peripheral cytokine levels 
are e.g. smoking, gender, age, diet, weight, physical activity, sleep disturbance, alcohol 
consumption, smoking and last but not least antipsychotic and other medication (Irwin, 
2002; Kronfol, 2002; Hinze-Selch and Pollmacher, 2001). Thus, immunological findings 
based on cytokine measurements in schizophrenic patients have to be interpreted with care. 
An increased B cellular immune response accompanied by a reduced T cellular immunity 
was repeatedly described in acute schizophrenia (Maino et al., 2007; Steiner et al., 2010). 
Based on the currently available data, the T cell immunity cannot clearly be associated with 
the Th1, Th2, Th17 or the Treg subset (Drexhage et al., 2010). However, increasing evidence 
points to an activation of circulating monocytes in schizophrenia (Drexhage et al., 2010; 
Drexhage et al., 2011). 
2.4.2 Depression 
The so-called sickness behaviour is the non-specific reaction to infection and inflammation. 
Sickness behaviour is characterised by weakness, malaise, listlessness, inability to 
concentrate, lethargy, decreased interest in the surrounding, and reduced food intake – all of 
which are depression-like symptoms. Thus, sickness behaviour was proposed to be a model 
of major depression (Dantzer, 2001). The sickness-related psychopathological 
symptomatology during infection and inflammation is mediated by cytokines such as IL-1, 
IL-6, TNF-, and IFNg. Their active pathway from the peripheral immune system to the 
brain is via afferent neurons and through direct targeting at amygdala and other brain 
regions after diffusion at the circumventricular organs and choroid plexus (Dantzer, 2001). 
Clinical evidence also shows that the changes in cognition and mood that are an integral 
part of major depression are also caused by these cytokines (Capuron et al., 1999). Important 
lessons regarding the involvement of elevated pro-inflammatory cytokines in the 
pathophysiology of depression can be learned from IFN-a administration in patients 
suffering from malignant melanoma or hepatitis C (Myint et al., 2009). Another important 
impact comes from rheumatoid arthritis research, where a complex pro-inflammatory 
immune state is frequently accompanied with depressed mood (Bruce, 2008). To underline 
the functional relationship between an inflammatory process and depression, several 
studies have demonstrated the anti-depressant effect of anti-inflammatory drugs (Tyring et 
al., 2006; Uguz et al., 2009). These findings resulted in clinical trials demonstrating the 
efficacy of non-steroidal anti-inflammatory drugs as add-on treatment of major depression 
(Müller et al., 2006; Akhondzadeh et al., 2009). On the other hand, antidepressants have 
significant anti-inflammatory effects, as recently reviewed by Janssen and colleagues 
(Janssen et al., 2010); they normalize elevated levels of circulating proinflammatory 
cytokines like IL-6, TNF-a, IFN-g, and IL-1, again indicating that the activation of the 
immune system may be directly involved in the pathophysiology of depression. Recent even 
demonstrate the possible usefulness of antidepressants to treat rheumatoid arthritis (Sacre et 
al., 2010). 
Beside these indirect lines of evidence for the involvement of an immune process in the 
pathophysiology of depression, there is a large body of findings of an activation of the 
immune system in depressed patients. The most frequently investigated immune 
parameters in patients suffering from major depression is IL-6. Most of the publications 
report a marked increase of in-vitro IL-6 production or serum IL-6 levels in depressed 
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patients. Since IL-6 is a prominent marker of monocyte activity, a predominant activation of 
the monocyte/macrophage system in major depression was hypothesised (Smith and Maes, 
1995). Recent meta-analyses have clearly pointed out the evidence for elevated IL-6 levels in 
patients suffering from depression (Howren et al., 2009; Dowlati et al., 2010). Regarding the 
elevation of the inflammatory markers C-reactive protein (CRP), IL-1, IL-1RA and TNF-a, 
the two meta-analyses came to diverging results.  
IL-6 may be involved in the modulation of the HPA axis (Plata-Salaman, 1991). Activation of 
the HPA axis is one of the best-documented changes in major depression (Roy et al., 1987). 
Furthermore, the relationship between psychological or physical stress and an enhanced IL-
6 secretion in the peripheral immune system seems to be well established (Salas et al., 1990; 
LeMay et al., 1990; Zhou et al., 1993; Miyahara et al., 2000).  An impaired ability of stress 
coping is often observed in depressed patients. Thus, the high number of data showing 
elevated peripheral IL-6 levels in MD patients may be partly related to psychological stress.  
However, it should be recognized that an inherent heterogeneity exists in the aetiology of 
depression and different neurotransmitter systems may be disturbed. Based on the 
commonly accepted idea of major depression as heterogeneous group of disease entities, the 
group of Arolt investigated the difference between melancholic and non-melancholic major 
depression regarding their cytokine expression patterns (Rothermundt et al., 2001). They 
detected profound differences between these diagnostic subgroups: Non-melancholic 
patients showed increased counts of leukocytes, lymphocytes and NK-cells in the acute 
stage of disease and after several weeks of treatment, while their in vitro production of the 
cytokines was unchanged. Melancholic patients on the other hand had normal cell counts 
but a decreased in vitro production of IL-2, IFN-, and IL-10 during the acute stage of 
disease. Following clinical improvement, the cytokine production patterns normalised in 
these patients.  
3. Inflammation-endocrinology and metabolism interaction 
Apart from all the mechanisms discussed above regarding how inflammation itself could be 
detrimental to the brain and how inflammatory response system (IRS) is involved in 
psychiatric disorders, the interaction between IRS and endocrine system and metabolism 
could induce greater degree of damage to the brain. Among the different endocrine systems, 
this chapter will be focused on the stress hormones system which is the most involved in 
inflammatory reaction. In the same manner, among the different metabolic pathways, the 
tryptophan metabolism and glycolysis pathways will be mainly discussed in this chapter 
due to their significant involvement in neurochemical changes related to psychiatric 
disorders. 
3.1 Inflammation and stress hormones interaction 
Hypothalamo-pituitary-adrenal (HPA) axis is the key stress hormone axis which has 
interaction with immune activation and inflammation. Investigations of the role of the HPA 
axis in the psychopathology of depression commenced over 40 years ago when it was 
reported that depressed patients have a higher circulating plasma cortisol concentration 
than those that are not depressed (Board et al., 1957; Sachar et al., 1970).  It was discovered 
that this synthetic glucocorticoid would normally suppress the secretion of cortisol by 
activating hypothalamic and pituitary glucocorticoid receptors thereby suppressing the 
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secretion of corticotrophin releasing factor (CRF) and adrenocorticotrophic hormone 
(ACTH), which in turn, reduced the activation of the adrenal cortex and the release of 
cortisol. The mechanism whereby these changes occurred was explained in terms of a 
negative feed-back loop whereby the raised plasma glucocorticoid concentration controls 
the further release of the steroid. However, it soon became apparent that in patients with 
major depression, the negative feed-back loop ceased to function due to the desensitization 
of the central glucocorticoid receptors. The negative dexamethasone suppression test 
thereby became a diagnostic marker of melancholic depression (Carroll et al., 1968a, b). As 
in major depression, it was reported in a systematic review that the evidence for elevated 
basal cortisol was consistently observed in first-episode, drug-naïve schizophrenia patients 
(Bradley and Dinan, 2010) although some studies reported negative finding (Strous et al., 
2004).  
It is frequently assumed that the synthetic glucocorticoids such as dexamethasone, act on 
glucocorticoid receptors in an identical manner to the natural glucocorticoids such as 
cortisol. This may not be the case. Dexamethasone acts primarily on the glucocorticoid 
receptors in the anterior pituitary, does not readily enter the brain and therefore differs 
substantially from natural glucocorticoids that activate both mineralocorticoid and 
glucocorticoid receptors (Trapp and Holsboer, 1996). There is also evidence that while 
dexamethasone may reduce the release of CRF, it does not suppress the release of arginine 
vasopressin (AVP). There is evidence that AVP, not CRF, is the main activator of the HPA 
axis due to chronic stress and major depression (Scott and Dinan, 1998). Although very little 
has been studied on CRF in schizophrenia, there are reports regarding increase AVP in 
schizophrenia (de Leon et al., 1994; Raskind et al., 1975). The increased action of AVP is 
further exacerbated by the action of IL-1 and IL-6; chronic immune activation is related 
more to AVP than CRF in the activation of the anterior pituitary (Raber and Bloom, 1994). In 
this way, chronic immune activation could induce abnormal HPA axis in both depression 
and schizophrenia.  
On the other hand, recent in vivo evidence suggests that stress-induced elevation of 
glucocorticoids also enhances immune function within the central nervous system (CNS) 
through microglia activation and proliferation and with a loss in the number and volume of 
astrocytes (Czeh et al., 2006). Animal studies show that stress induces an enhanced 
expression of proinflammatory factors such as IL-1 (Pugh et al., 1999), macrophage 
migration inhibitory factor (MIF) (Bacher et al., 1998; Niino et al., 2000; Suzuki et al., 2000) 
and COX-2 (Madrigal et al., 2003) in the brain. Elevation of these proinflammatory factors is 
accompanied by dendritic atrophy and neuronal death within the hippocampus (Sapolsky, 
1985; Woolley et al., 1990), which are also found in brains of subjects with major depression. 
These detrimental effects of glucocorticoids in the CNS are mediated by a rise in 
extracellular glutamate (Aucott, 1994; Stein-Behrens et al., 1994) and subsequent over-
stimulation of the NMDA (N-methyl-D-aspartate) receptor. Such an over-stimulation of the 
NMDA receptor results in excitotoxic neuronal damage (Takahashi et al., 2002). Nair and 
Bonneau could demonstrate that restraint-induced psychological stress stimulates 
proliferation of microglia, which was prevented by blockade either of corticosterone 
synthesis, of the glucocorticoid receptor, or of the NMDA receptor (Nair and Bonneau, 
2006). These data show that stress-induced microglia proliferation is mediated by 
corticosterone-induced and NMDA receptor-mediated activation within the CNS. 
Moreover, NMDA receptor activation during stress leads again to increased expression of 
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COX-2 and PGE2. Both, COX-2 and PGE2 per se are able to stimulate microglia activation. 
Therefore, a vicious circle may be induced, if the stress response is not limited, as in most of 
the psychiatric disorders. 
3.2 Inflammation-stress hormones-tryptophan metabolism interaction 
Not only the interaction between inflammation and stress hormones but also their further 
interaction with tryptophan metabolism brings the whole complex pathway to attention in 
psychiatric disorders. Tryptophan is an essential amino acid which has indole ring structure 
and is obtained from the dietary source approximately 20 nmol/day. The reference value of 
plasma tryptophan ranges from 45 to 60 nmol/l (Eynard et al., 1993). Of those, 50 to 85% are 
bound to albumin in unstable manner (Yuwiler et al., 1977). Serotonin is synthesized from 
about 1% of the available tryptophan in the body. Main serotonin synthesis occurred in the 
enterochromaffin cells in the gut and 10 to 20% occurred in the brain after crossing blood 
brain barrier (BBB). The central availability of tryptophan mainly depends on the 
competition by the large amino acids at the transport across BBB and partially depends on 
the cerebral demand (Fernstrom, 1977). About 99% of tryptophan is metabolized in the liver 
by the tryptophan 2,3-dioxygenase (TDO) (Watanabe et al., 1980). The TDO activity is 
mainly controlled by the tryptophan level itself and therefore, its activity is generally stable.  
After tryptophan is catabolised into kynurenine (KYN), it is further catabolised into 3-
hydroxy-kynurenine (3HK) by kynurenine-3-monooxygenase (KMO) enzyme. After 3HK, 
further degradation continues to 3-hydroxyanthranilic acid (HAA) through the action of 
kynureninase. After that, the catabolism proceed either into complete oxidation pathway 
and forms adenosine triphosphate (ATP) which occurs mainly in the liver, or into quinolinic 
acid (QUIN) which is finally degraded into nicotinamide adenine dinucleotide (NAD). From 
the complete oxidation pathway, picolinic acid (PIC) is also formed in small quantity. In 
physiological condition, the catabolism goes mainly to ATP formation and only minor 
portion goes to NAD formation (Leklem, 1971). KYN can also be catabolised by the 
kynurenine aminotransferases (KATs) into kynurenic acid (KYNA) (Figure-2). This 
metabolism in the liver is more or less stable and age and gender has influence on this 
metabolism (Leklem, 1971) especially in terms of excretion of the metabolites of further 
downward KYN pathway. The formation of tryptophan to nicotinic acid and its derivatives 
is important and the impaired condition could result in the disease pellagra. Moreover, since 
ATP formation in the cells is dependent on NAD, depletion of NAD is fatal to the cells 
especially if the cell is under stress. In normal state, to get normal NAD requirement, QUIN 
synthesis occurs only transiently in the liver and QUIN does not accumulate in the 
hepatocytes (Bender, 1989).  
Since KYN itself could be transported across the blood brain barrier, on top of the 
kynurenine formed in the brain by tryptophan breakdown, extra KYN is available from the 
periphery for further kynurenine metabolism in the brain. Sixty percent of brain KYN was 
contributed from the periphery (Gal and Sherman, 1980). In the brain, tryptophan 
catabolism occurs mainly in the astrocytes and microglia (Grant and Kapoor, 1998; Grant et 
al., 2000; Heyes et al., 1996).  Although some neurons also posses indoleamine 2,3-
dioxygenase (IDO) and/or TDO2 (Miller et al., 2004), neurons are not the main sites of 
kynurenine pathway in the brain.  While the human astrocytes are shown to produce mainly 
KYNA because of lack of KMO enzyme, microglia and macrophages produce mainly QUIN 
(Guillemin et al., 2001; Guillemin et al., 2000; Guillemin et al., 2005a). The astrocytes 
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metabolize QUIN produced by the neighbouring microglia (Guillemin et al., 2001). In the 
brain, in physiological condition without immune challenge, as in the liver, this kynurenine 
pathway may serve mainly for glycogen storage and synthesis of small amount of NAD 
required for the central nervous system (Leklem, 1971). 
 
 
Fig. 2. Immune-NeuroEndocrine-Tryptophan Interaction (adapted from Myint et al, 2009) 
In case of inflammation, infection or oxidative stress which activates the enzyme IDO in the 
extrahepatic tissues, such as, lungs, placenta, kidneys, spleen, blood and the brain (Heyes et 
al., 1993; Mellor and Munn, 1999), the extrahepatic tryptophan metabolism shifts the 
tryptophan metabolism away from the liver (Moffett et al., 1998). In this case, tryptophan 
breakdown through KYN pathway occurs mainly in the blood and lymphoid tissues 
(Moffett and Namboodiri, 2003). The IDO activity is enhanced by pro-inflammatory 
cytokines such as interferon- (IFN) (Carlin et al., 1987; Yasui et al., 1986), and inhibited by 
the anti-inflammatory cytokine IL4 (Musso et al., 1994). As discussed above, in case of stress 
or related conditions, such as inflammation, HPA axis activity will be enhanced and 
glococorticoid secretion is increased. In this situation, TDO activity is further enhanced by 
glucocorticoids (Knox, 1951; Salter and Pogson, 1985). Although not many studies have been 
carried out on the interaction between stress hormones or glucocorticoids and TDO, some 
studies have demonstrated that hepatic TDO activity can be enhanced via glucocorticoid 
mediated transcriptional activation (Nakamura et al., 1987), although hepatic heme is the 
essential requirement in this activation (Ren and Correia, 2000). This activation of TDO by 
stress hormone will induce further increase in tryptophan breakdown, and as a result, the 
KYN formation becomes much higher than physiological condition. Since the liver cell 
uptake of KYN is not efficient for extrahepatic KYN, the further KYN pathway mainly 
occurs extrahepatically. The activity of KMO is also enhanced by pro-inflammatory 
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cytokines (Mellor and Munn, 1999). Therefore, in case of inflammation, the formation of 
3HK becomes enhanced much faster than KYNA formation and the balance between 
formation of 3HK and KYNA shifted to 3HK side. In the presence of inflammation, activated 
monocytes are found to be the robust producers of QUIN (Chiarugi et al., 2001). During 
inflammation, QUIN production persists till the inflammatory process is completed (Heyes 
and Lackner, 1990). Since some of the KYN metabolites activate inflammatory reaction, this 
could further prolong the QUIN synthesis (Melillo et al., 1993), whereas some of the 
metabolites inhibit the proliferation of T cells and NK cells (Frumento et al., 2002) and 
inhibit the further inflammatory process and stop further QUIN formation. In this way, 
immune tolerance is achieved through tryptophan depletion and homeostasis in KYN 
pathway is maintained. 
Therefore, in case of acute inflammation, the transient disturbances in the tryptophan 
metabolism will take place through; (1) effect of inflammatory mediators on IDO activity 
and (2) interaction between glucocorticoid and TDO activity. This might be one of the 
reasons that could induce sickness behaviour during acute inflammation. In fact, all those 
changes are some how necessary for the body homeostatic mechanism to regulate the 
inflammatory response and to generate the energy that the body requires during acute 
inflammation. 
4. Inflammation-tryptophan metabolism-neurochemicals interaction 
The frontiers in the field of interaction between tryptophan metabolism and neurochemicals 
proposed that the tryptophan shunted away from the serotonin synthesis towards 
degradation into kynurenine as a mechanism involved in the psychiatric disorders (Lapin 
and Oxenkrug, 1969; Mangoni, 1974). Based on this mechanism several studies have been 
carried out in tryptophan and kynurenine changes in depressive disorders. One very early 
study on plasma kynurenine levels in depressed patients and controls demonstrated lack of 
significant difference between the groups (Wood et al., 1978), whereas, another study on 
plasma neutral amino acids and tryptophan in mania and depressed patients demonstrated 
reduced tryptophan availability in the patients compared to healthy controls (Moller and 
Amdisen, 1979). At the same time, a post mortem study was carried out on tryptophan 
metabolism and schizophrenia. The investigators reported the increased tryptophan and 
kynurenine in the brain of schizophrenia without evidence of generalized deficit in 
serotonin (Jospeh et al., 1979). 
After the discovery of the effect of pro-inflammatory cytokines on IDO enzyme activity 
(Carlin et al., 1987; Yasui et al., 1986) and the interaction between glucocorticoids and TDO 
activity (Knox, 1951; Nakamura et al., 1987; Salter and Pogson, 1985), the link between 
inflammatory state, tryptophan metabolism and serotonergic neurotransmission became of 
interest in the field of psychoneuroimmunology. Somehow, the report of a study on QUIN 
and kynurenine pathway metabolism in different inflammatory and non-inflammatory 
neurological diseases brought this field forward although it failed to show the significant 
association between metabolites in the CSF and psychiatric disorder such as depression 
(Heyes et al., 1992). Since that time many research groups focussed on tryptophan 
breakdown and psychiatric disorders such as depression, anxiety disorders and 
schizophrenia. 
www.intechopen.com
 
Psychiatric Disorders – Worldwide Advances 
 
178 
4.1 Interaction with serotonergic neurotransmission 
As discussed above, in the brain, the inflammatory state enhanced tryptophan breakdown 
and that in turn induces low availability of tryptophan for serotonin synthesis (Lapin and 
Oxenkrug, 1969; Mangoni, 1974). Unlike TDO, the enzyme IDO is not specific to tryptophan 
alone but degrades any compound with indole ring. Therefore, in case of inflammation and 
IDO activation, serotonin is degraded not only by monoamine oxidase (MAO) into 5-
hydroxyindole acetic acid (5HIAA), but also by IDO into formyl-5-hydroxykynuramine 
(f5OHKYM) (Pertz and Back, 1988). This further reduces the serotonin availability for 
optimal serotonergic neurotransmission.  
The earliest study on interaction between pro-inflammatory cytokines, tryptophan 
degradation and depression was carried out on patients with chronic active hepatitis C who 
were treated with IFN which is a pro-inflammatory cytokine (Maes et al., 2001) . The 
investigators have demonstrated the association between increased in serum IL-8, serum 
kynurenine to tryptophan ratio that indicates increased tryptophan breakdown and 
depression rating scales. Unfortunately, there was no data on serotonergic 
neurotransmission. However, another study on IFN therapy but in melanoma patients, 
also demonstrated that, in antidepressant-free patients under IFN treatment, the decreases 
in serum tryptophan correlated with depressive, anxious, and cognitive symptoms, but not 
neurovegetative or somatic symptoms (Capuron et al., 2003). The author stated that those 
associations were not observed in those treated with paroxetine, a selective serotonin 
reuptake inhibitor (SSRI). At least, this study indirectly indicated that the development of 
symptoms in association with serum tryptophan level was related to insufficient 
serotonergic neurotransmission since paroxetine treated patients showed lack of those 
associations.  
The occurrence of depression during pregnancy or post-partum period was also 
considered to be associated with inflammatory state (Maes et al., 2000) and serotonergic 
neurotransmission (Gu et al., 2003). A study demonstrated that the tryptophan 
breakdown was increased in pregnant women than non-pregnant women and the 
difference was more pronounced in those with anxiety and depression (Maes et al., 2002). 
Another study also demonstrated that low mood in post-partum period was associated 
with continuously low serum tryptophan after the delivery due to increased degradation 
into kynurenine (Kohl et al., 2005). Taken altogether, there is again, another circumstantial 
evidence of relationship between inflammatory state, tryptophan degradation and 
serotonergic neurotransmission. 
There is only one study which investigated on association between complete triad of 
inflammation, kynurenine level and serotonin in the blood of the patients with pure major 
depression (Mackay et al., 2009). This study demonstrated the association between 
kynurenine levels and degree of depression in the patients treated with SSRI fluoxetine. 
Here again, there is no proof of direct association between inflammation, tryptophan 
degradation and serotonergic abnormalities in depression. Regarding the association 
between tryptophan degradation and serotonergic neurotransmission in schizophrenia, only 
one post-mortem study (Jospeh et al., 1979) and one CSF analyses study were carried out 
(Issa et al., 1994). Although the post-mortem study could show the increased tryptophan 
and kynurenine in the brain of the patients, and CSF study could demonstrate the reduced 
tryptophan level in the schizophrenia group, both studies failed to demonstrate the 
association with serotonergic neurotransmission. 
www.intechopen.com
Interaction Between Inflammatory State and  
Neurochemical Changes in Major Psychiatric Disorders 
 
179 
Although there is no experimental study showing the direct relationship between increased 
IDO activity, tryptophan breakdown and reduced serotonergic neurotransmission, the 
circumstantial evidences from human studies in depression indicated the association 
between pro-inflammatory states, increased tryptophan breakdown and impaired 
serotonergic neurotransmission. 
4.2 Interaction with glutamatergic and dopaminergic neurotransmission 
The disturbance in glutamatergic neurotransmission is one of the common pathways 
involved in the pathophysiology of depression and schizophrenia. The first findings 
indicating the involvement of glutamatergic neurotransmission in mood disorders based on 
the preclinical data with N-methyl-D-aspartate receptor (NMDA-R) antagonist, ketamine 
(Silvestre et al., 1997). The antidepressant effect of NMDA-R antagonist, ketamine, was also 
reported in depressed patients (Berman et al., 2000). The hypofunctioning of glutamatergic 
neurotransmission as part of the pathophysiology of schizophrenia was proposed based on 
the finding of low glutamate concentrations the CSF of schizophrenia patients (Kim et al., 
1980). Unlike in depression, NMDA-R antagonist, ketamine could enhance the 
neurochemical reaction of amphetamine-induced dopamine release in healthy controls 
mimicking the neurochemical reaction in schizophrenia patients (Kegeles et al., 2000). 
As explained before, during inflammation and enhanced tryptophan breakdown, extra 
amount of peripheral KYN becomes available for the further KYN metabolism in the brain, 
since KYN can be transported across BBB. In case of pro-inflammatory state in the brain, the 
KYN metabolism in the astrocytes and microglia might also be enhanced. Therefore, the 
kynurenine pathway is highly activated in the brain. The KYN metabolites contribute 
directly to the neuroprotective-neuro-degenerative changes in the brain through direct 
effects on several neurotransmissions.  The QUIN is a NMDA-R agonist (Bender and 
McCreanor, 1985) and accumulation of QUIN could result in excitotoxicity. It was reported 
in an in-vitro study that the metabolite QUIN could induce selective apoptosis to astrocytes 
(Guillemin et al., 2005b). 3HK causes neuronal apoptosis (Okuda et al., 1998) while QUIN 
causes excitotoxic neurodegenerative changes (Schwarcz et al., 1983). However, KYNA is 
the NMDA-R antagonist (Perkins and Stone, 1982) and is protective against excitotoxicity of 
QUIN (Kim and Choi, 1987).  
Therefore, the pro-inflammatory status in major depression would activate not only IDO 
(Carlin et al., 1987; Yasui et al., 1986) but also KMO enzyme activities (Mellor and Munn, 
1999) and this might in turn shift the KYN metabolism to the 3HK and QUIN arm with 
possible reduction in KYNA (Figure-2). The changes in NMDA-R agonist and antagonist, 
QUIN and KYNA might have impact on glutamatergic neurotransmission. Moreover, it was 
proposed that the increased in those toxic metabolites imbalanced to formation of KYNA 
might prime the astrocytes-microglia-neuronal network to be vulnerable to environmental 
factors such as stress. It was also proposed that, the imbalanced KYN pathway induced 
impaired glial-neuronal network might contribute to the recurrent and chronic nature of 
major depression (Myint and Kim, 2003). The neurotoxic metabolites might induce 
astrocytes apoptosis and certain neuronal apoptosis which would bring the glial-neuronal 
network weaker and reduction in syntheses of neurotrophic factors and prime the system to 
be vulnerable to stress and get psychiatric consequences. The loss of astrocytes might 
further induce glutermatergic abnormalities also through disturbance in glutamate-
glutamine metabolism. 
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In patients with major depression who are drug naïve or medication free for at least 4 
months, an imbalance between those neuroprotective and neurotoxic pathways with lower 
protective metabolite has been and demonstrated (Myint et al., 2007b). The ratio between 
KYNA and KYN (KYNA/KYN) which indicated how much of KYN would be degraded 
into KYNA was significantly lower in depressed patients than healthy controls. Moreover, 
6-week medication with currently available antidepressants, mainly, selective serotonin 
reuptake inhibitors (SSRIs) could not reverse the metabolic imbalance in KYN pathway back 
to normal. We have hypothesized that such an uncorrected imbalance with higher 3HK and 
QUIN to KYNA ratios, in the long term, might induce further loss of astrocytes and 
neurodegenerative changes that in turn induces the chronicity, treatment resistance and 
progression of the disease. In major depression, there are evidences of neurodegenerative 
changes and loss of astrocytes (Rajkowska et al., 1999). In addition, the decreased glutamate 
and glutamine levels in pregenual anterior cingulate cortex of depressed patients with 
associated severity of clinical symptoms have been reported (Auer et al., 2000; Rosenberg et 
al., 2005). 
Not only in adult depression but also in adolescent depression, the kynurenines seem to 
play a role. A recent study reported that in magnetic resonance (MR) spectroscopy in 
melancholic depressed adolescents, the choline levels which indicated the turnover of cells 
showed positive correlation with serum KYN and HAA/KYN ratio (Gabbay et al.). This 
study also demonstrated that the serum KYN and HAA/KYN ratios were significantly 
increased in those adolescents with melancholic depression than non-melancholic 
depression. Moreover, it was reported in this study that the serum KYN and HAA/KYN 
were positively correlated with depression scores. It could be concluded that the shift in 
KYN pathway more to the arm of 3HK, HAA and QUIN is involved also in adolescent 
melancholic depression. 
In case of cytokine therapy induced depression, such as, IFN therapy induced depression, 
increase in IL-6 and decrease in KYNA or increased in KYN/KYNA showed significant 
association with development of depressive symptoms (Wichers et al., 2005). However, 
another study showed that both KYNA and QUIN were increased in IFN treated patients 
(Raison et al.), although the ratio between metabolites from these two arms was not 
reported. Nevertheless, both studies indicated the enhanced TRP degradation and change of 
KYN metabolites after immune challenge with IFN and the depressive episodes were the 
consequences. 
Further evidences also arise from animal experiments regarding the association between 
inflammation, tryptophan metabolic pathway abnormalities and depression. O’Connor and 
group demonstrated that lipopolysaccharide induced depressive behaviour through the 
action of enhanced IDO enzyme activity (O'Connor et al., 2009c). This group also 
demonstrated in the bacille Calmette-Guérin (BCG) mouse model of depression (O'Connor 
et al., 2009b) that immune activation using BCG could induce depressive behaviour and 
activation of IDO enzyme activity followed by activation 3-hydroxyanthranillic acid oxidase 
(HAAO) enzyme which enhance degradation of HAA and that in turn enhances the 
formation of neurotoxic QUIN. Moreover, blockade of IDO was demonstrated to prevent 
the depressive behaviour. In another study, IFN knock-out mice did not show the 
depressive behaviour when challenged with BCG since IFN is the inducer of IDO enzyme 
(O'Connor et al., 2009a). These evidences indicate that manipulating the KYN pathway 
could be a novel therapeutic strategy for counteracting depression.  
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Regarding bipolar mania, increased expression of TDO2 in anterior cingulate gyrus of post-
mortem brain tissues from bipolar patients was reported (Miller et al., 2006). There is only 
one study reported on kynurenines changes in the plasma of bipolar mania patients (Myint 
et al., 2007a). It was reported that in bipolar mania patients, there was no significant 
reduction in KYNA, even though a trend of decrease was observed. Moreover, it was 
reported in that study that 6-week treatment with currently available mood stabilizers did 
not show any changes. Although the pro-inflammatory state in bipolar disorder was not 
clearly stated, there are some reports on pro-inflammatory state in bipolar disorders (Kim et 
al., 2007). The pro-inflammatory state induced kynurenines imbalance may also be involved 
in the pathophysiological mechanism of bipolar disorders. Further more detailed studies are 
still necessary to find out the interaction between immune status, tryptophan metabolism 
and neurotransmitter function in bipolar disorders. 
In case of schizophrenia, a study in post-mortem brain tissue in different cortical regions 
revealed increased KYNA levels in schizophrenic samples compared to a control sample, 
particularly in the prefrontal cortex (Schwarcz et al., 2001). Another investigation in the 
amygdala, a small and nonsignificant increase of KYNA in medicated schizophrenics was 
observed (Miller et al., 2006). Those studies raised a question as to whether the increase in 
KYNA might be associated with antipsychotic medication. However, the increased levels of 
KYNA was also observed in the CSF of schizophrenic patients (Erhardt et al., 2001). Since 
most of the patients in this study were drug-naive first-episode patients, this increase could 
not be caused by antipsychotic treatment. It was hypothesized that accumulation of KYNA 
may lead to schizophrenic symptoms (Erhardt et al., 2003). An experiment in rat 
demonstrated that KYNA concentration significantly reduced in hippocampus, striatum and 
prefrontal cortex after one month treatment with antipsychotics, haloperidol, clozapine and 
raclopride (Ceresoli-Borroni et al., 2006). This study also demonstrated that one year 
treatment with haloperidol still continue reduction in KYNA concentration in the interstitial 
fluid of the rat brain.  
Since prefrontal cortex area is involved in the pathophysiology of schizophrenia (Andreasen 
et al., 1992) the increase in KYNA might be involved in pathophysiological mechanism. 
Since KYNA is the NMDA-R antagonist, it could be concluded that the development of 
psychotic symptoms are associated NMDA-R antagonism. KYNA is the antagonist of all 
three ionotropic excitatory amino acid receptors (Perkins and Stone, 1982). Even though 
KYNA is generally considered as protective metabolite against QUIN, its abnormal 
accumulation beyond physiological level could induce glutamatergic hypo-functioning and 
might disturb cognitive function (Olney et al., 1991). Moreover, while one of tryptophan 
metabolites 5-hydroxy indole (5HI) activates the 7-nicotinic acetylcholine receptor 
(7nAchR) and induces glutamate release (Mannaioni et al., 2003; Zwart et al., 2002), KYNA 
is an antagonist of 7nAchR (Hilmas et al., 2001). Since KYNA down-regulate the 
permissive role of 5HI activation on 7nAchR, the accumulation of KYNA could suppress 
7nAchR function and induce disruption of auditory sensory gating (Shepard et al., 2003). 
In addition, it was reported that KYNA inversely regulates the dopaminergic tone (Wu et 
al., 2007). In this context, 5HI and KYNA exert synergistic action on dopaminergic 
neurotransmission. These interactions of KYNA with other neurotransmitters such as 5HI 
could contribute to some behavioural or cognitive consequences such as psychosis and 
cognitive impairment other than neurodegenerative changes. 
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Not only the positive symptoms but also the negative symptoms are part of the 
psychopathology of schizophrenia. There are also considerable evidences of loss of brain 
volume in schizophrenia (Takahashi et al., 2009). Unfortunately, the tryptophan research in 
schizophrenia most of the studies concentrated only on KYNA. There is only one group 
reported on 3HK (Condray et al., 2011; Yao et al.) although no clear change was demonstrated 
and no balance between potentially neuroprotective metabolite, KYNA, and neurotoxic 
metabolites such 3HK was investigated. Nevertheless, this group has demonstrated the 
association between 3HK and (1) total symptoms score at the time of recruitment, and (2) 
response of positive symptoms to 4-week neuroleptic treatment in first episode neuroleptic 
naïve schizophrenia patients. The associations between negative symptoms, brain volume 
changes and potentially neurotoxic metabolites in the pathophysiology have been ignored in 
schizophrenia research. Most of the therapeutic possibilities proposed are to manipulate 
KYNA (Erhardt et al., 2009). Without knowledge of interaction between different potentially 
neuroprotective and potentially neurotoxic metabolites, manipulation of just one metabolite 
would raise an issue regarding the potential untoward neurotoxic effects in the patients. Our 
recent finding in medication naive schizophrenia patients indicated increased 3HK and 
decreased KYNA in the plasma compared to healthy controls (Myint et al., 2011) and it was 
reversed by 6 weeks antipsychotic treatment. This would be the indirect indicator of 
accumulation of 3HK due to enhanced KMO activity induced by pro-inflammatory statues in 
schizophrenia. As discussed in depressive disorders, this might further lead to increase 
NMDA-R agonist QUIN in certain brain areas and excitotoxicity. To answer the question on 
clear interaction of inflammation, tryptophan breakdown and glutamatergic 
neurotransmission is more complicated. 
4.3 Interaction with cholinergic and adrenergic neurotransmission 
In pro-inflammatory state, although the balance between 3HK and KYNA might generally 
shift to 3HK arm, because of the general increase of KYN the formation of KYNA may also 
be higher than normal state. Since it is NMDA-R antagonist, well balanced increase may 
counteract the negative effects of QUIN through NMDA-R and the homeostasis will be 
maintained. As mentioned before, in schizophrenia, there is considerable evidence of 
increase formation of KYNA observed both in CSF (Erhardt et al., 2001) and at certain areas 
of the brain (Schwarcz et al., 2001). Also a study on IFN treated patients show increase of 
both KYNA and QUIN in the CSF (Raison et al., 2010). In those cases, consequences of 
increase KYNA may induce negative impact on other neurotransmissions. 
Apart from the interaction with 7nAchR, the metabolites 5HI and KYNA also have 
interaction with non-7nAchR. The metabolite 5HI was reported to inhibit non-7nAchR 
mediated release of noradrenaline (NA), dopamine (DA) and acetylcholine (Ach) (Grilli et 
al., 2006). Similarly, KYNA inhibit the function of the non-7nAchR by reducing the 
expression of those receptors (Hilmas et al., 2001). Therefore, inhibition of non-7nAchR by 
increased KYNA could also disturb cholinergic and noradrenergic neurotransmission.  
Therefore, inflammatory state induced increased in KYNA could play part of the 
pathophysiology of noradrenergic neurotransmission in psychiatric disorders.  
5. Future perspectives 
The findings discussed above are the clear evidences that the interaction between immune 
activation and tryptophan metabolism and kynurenine pathway is involved in 
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pathophysiology of major psychiatric disorders. The manipulation of this metabolism is of 
interest for future therapeutic development and several studies are focusing on this aspect. 
There are some enzyme inhibitors that are already developed. However, it is important to 
consider the possible occurrence of imbalance between different metabolites when a 
particular enzyme is blocked or manipulated to enhance or reduce the particular metabolite. 
Therefore, such manipulation should be carried out with clear indication such as evidence of 
change in metabolites or ratios between metabolites as biomarkers. Moreover, close 
monitoring on those changes during therapy would also be necessary. Since TRP 
metabolism is the metabolism in which there is crosstalk between peripheral and central, 
use of peripheral markers as indirect evidence of central changes for diagnostic and 
prognostic purpose is not unrealistic.   
Future studies should be carried out not only on manipulation of the metabolism for 
therapeutic purpose but also on the use of KYN pathway metabolites as biomarkers in 
evidence based management for early detection, choice of correct medication and 
monitoring. The normal values of those metabolites in different population are not yet 
known. Clear association between central and peripheral markers should be investigated. 
The validation of the usefulness of those biomarkers should be carried out in multicentre 
approach. Since currently available technologies to detect those metabolites are expensive 
and sophisticated, the studies on development of user-friendly and cost-effective 
technologies for detection of those metabolites are also necessary to be carried out. 
The indirect manipulation of this pathway through anti-inflammatory medication could be 
considered as another therapeutic strategy. The indirect manipulation of this pathway 
through anti-inflammatory medication could also be another strategy. The use of COX-2 
inhibitor celecoxib as add-on therapy to standard anti-depressant or anti-psychotics is a 
promising approach. The prevention of inflammation and oxidative stress using some 
medications such as n3-fatty acid which is more or less harmless or lifestyle intervention 
through diet, exercise and mindfulness practices could also be an option. However, this type 
of treatment should start timely and kynurenines could be the possible biomarkers as early 
indicators of immune-metabolic-neurochemical imbalances. 
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